Galunisertib plus gemcitabine may improve overall survival and progression-free survival compared to gemcitabine alone in patients with pancreatic cancer, according to a study presented at the American Association for Cancer Research Annual Meeting (April 16-20, 2016; New Orleans, LA).
Welcome to Oncology Newswatch's case report exploration. This interactive case report will engage your experience and knowledge about details of a given case. Along the way, we will provide details and at the end, we will share the patient's outcome.
Debulking metastases of pancreatic neuroendocrine tumors (PNETs) may be effective at a threshold of greater than or equal to 70%, indicating that liver debulking criteria could possibly be extend to this threshold, according to a recent study.
The addition of radiation therapy to chemotherapy improved overall survival (OS) in patients with unresected locally advanced pancreatic cancer, according to research presented at the 2017 ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).
A new tyrosine kinase inhibitor (TKI) in combination with gemcitabine does not improve overall survival (OS) any more than gemcitabine alone for patients with advanced pancreatic cancer, according to a study published in The Lancet Oncology (published online March 2017; doi:10.1016/S1470-2045(17)30084-0).
Adding radiation to chemotherapy regimens may not improve overall survival compared with chemotherapy alone in patients with locally advanced pancreatic cancer, according to results from a clinical trial.